tiprankstipranks
Advertisement
Advertisement
Kura Oncology CEO buys $1.11M in common stock
PremiumThe FlyKura Oncology CEO buys $1.11M in common stock
10d ago
Kura Oncology reports Q2 EPS (77c), consensus (88c)
Premium
The Fly
Kura Oncology reports Q2 EPS (77c), consensus (88c)
11d ago
Kura Oncology price target raised to $31 from $30 at BofA
Premium
The Fly
Kura Oncology price target raised to $31 from $30 at BofA
11d ago
Kura Oncology Enhances Executive Severance, Change-in-Control Terms
PremiumCompany AnnouncementsKura Oncology Enhances Executive Severance, Change-in-Control Terms
29d ago
Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data
Premium
Ratings
Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data
1M ago
Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC
Premium
Ratings
Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC
1M ago
Kura Oncology Shareholders Approve Expanded Equity Incentive Plans
PremiumCompany AnnouncementsKura Oncology Shareholders Approve Expanded Equity Incentive Plans
3M ago
Analyst Reiterates Buy on Kura Oncology, Maintains $40 Price Target on Expanding Darlifarnib Combination Platform
Premium
Ratings
Analyst Reiterates Buy on Kura Oncology, Maintains $40 Price Target on Expanding Darlifarnib Combination Platform
3M ago
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
Premium
The Fly
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100